{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T01:37:11Z","timestamp":1789868231150,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR40153\/BTIS\/137\/8\/2021  and BT\/PR40195\/BTIS\/137\/58\/2023"],"award-info":[{"award-number":["BT\/PR40153\/BTIS\/137\/8\/2021  and BT\/PR40195\/BTIS\/137\/58\/2023"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11030-024-11063-9","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T10:55:48Z","timestamp":1733655348000},"page":"4579-4593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Repurposed drugs as PCSK9-LDLR disruptors for lipid lowering and cardiovascular disease therapeutics"],"prefix":"10.1007","volume":"29","author":[{"given":"Shelly Singhal","family":"nee Shelly Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daman","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamna","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"key":"11063_CR1","unstructured":"Multiple Cause of Death Data on CDC WONDER. https:\/\/wonder.cdc.gov\/mcd.html. Accessed 19 Nov 2024"},{"key":"11063_CR2","doi-asserted-by":"publisher","first-page":"e051121189015","DOI":"10.2174\/1573403X16999201210200342","volume":"17","author":"A Alloubani","year":"2021","unstructured":"Alloubani A, Nimer R, Samara R (2021) Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review. Curr Cardiol Rev 17:e051121189015. https:\/\/doi.org\/10.2174\/1573403X16999201210200342","journal-title":"Curr Cardiol Rev"},{"key":"11063_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s J-P et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154\u2013156. https:\/\/doi.org\/10.1038\/ng1161","journal-title":"Nat Genet"},{"key":"11063_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1573403X13666170804150954","volume":"13","author":"A Hachem","year":"2017","unstructured":"Hachem A, Hariri E, Saoud P et al (2017) The role of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in cardiovascular homeostasis: a non-systematic literature review. Curr Cardiol Rev 13:274\u2013282. https:\/\/doi.org\/10.2174\/1573403X13666170804150954","journal-title":"Curr Cardiol Rev"},{"key":"11063_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/tpj.2016.3","volume":"17","author":"Q Feng","year":"2017","unstructured":"Feng Q, Wei WQ, Chung CP et al (2017) The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J 17:204\u2013208. https:\/\/doi.org\/10.1038\/tpj.2016.3","journal-title":"Pharmacogenomics J"},{"key":"11063_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3909\/ricm19S1S0002","volume":"19","author":"EM Roth","year":"2018","unstructured":"Roth EM, Davidson MH (2018) PCSK9 inhibitors: mechanism of action, efficacy, and safety. Rev Cardiovasc Med 19:31\u201346. https:\/\/doi.org\/10.3909\/ricm19S1S0002","journal-title":"Rev Cardiovasc Med"},{"key":"11063_CR7","doi-asserted-by":"publisher","first-page":"e0225780","DOI":"10.1371\/journal.pone.0225780","volume":"14","author":"F Guarnieri","year":"2019","unstructured":"Guarnieri F, Kulp JL, Kulp JL, Cloudsdale IS (2019) Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations. PLoS ONE 14:e0225780. https:\/\/doi.org\/10.1371\/journal.pone.0225780","journal-title":"PLoS ONE"},{"key":"11063_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3349\/ymj.2015.56.5.1251","volume":"56","author":"D-K Min","year":"2015","unstructured":"Min D-K, Lee H-S, Lee N et al (2015) In silico screening of chemical libraries to develop inhibitors that hamper the interaction of PCSK9 with the LDL receptor. Yonsei Med J 56:1251\u20131257. https:\/\/doi.org\/10.3349\/ymj.2015.56.5.1251","journal-title":"Yonsei Med J"},{"key":"11063_CR9","doi-asserted-by":"crossref","unstructured":"Molecules | Free Full-Text | A new strategy for rapidly screening natural inhibitors targeting the PCSK9\/LDLR Interaction In Vitro. https:\/\/www.mdpi.com\/1420-3049\/23\/9\/2397. Accessed 17 Jan 2024","DOI":"10.3390\/molecules23092397"},{"key":"11063_CR10","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.jlr.2022.100293","volume":"63","author":"AK Suchowerska","year":"2022","unstructured":"Suchowerska AK, Stokman G, Palmer JT et al (2022) A novel, orally bioavailable, small-molecule inhibitor of PCSK9 with significant cholesterol-lowering properties in vivo. J Lipid Res 63:100293. https:\/\/doi.org\/10.1016\/j.jlr.2022.100293","journal-title":"J Lipid Res"},{"key":"11063_CR11","doi-asserted-by":"publisher","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","volume":"7","author":"Y Pan","year":"2017","unstructured":"Pan Y, Zhou Y, Wu H et al (2017) A therapeutic peptide vaccine against PCSK9. Sci Rep 7:12534. https:\/\/doi.org\/10.1038\/s41598-017-13069-w","journal-title":"Sci Rep"},{"key":"11063_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","volume":"8","author":"C Gustafsen","year":"2017","unstructured":"Gustafsen C, Olsen D, Vilstrup J et al (2017) Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun 8:503. https:\/\/doi.org\/10.1038\/s41467-017-00568-7","journal-title":"Nat Commun"},{"key":"11063_CR13","doi-asserted-by":"publisher","first-page":"29931","DOI":"10.1038\/srep29931","volume":"6","author":"C Lammi","year":"2016","unstructured":"Lammi C, Zanoni C, Aiello G et al (2016) Lupin peptides modulate the protein-protein interaction of PCSK9 with the low density lipoprotein receptor in HepG2 cells. Sci Rep 6:29931. https:\/\/doi.org\/10.1038\/srep29931","journal-title":"Sci Rep"},{"key":"11063_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.chembiol.2021.08.012","volume":"29","author":"ME Brousseau","year":"2022","unstructured":"Brousseau ME, Clairmont KB, Spraggon G et al (2022) Identification of a PCSK9-LDLR disruptor peptide with in vivo function. Cell Chem Biol 29:249-258.e5. https:\/\/doi.org\/10.1016\/j.chembiol.2021.08.012","journal-title":"Cell Chem Biol"},{"key":"11063_CR15","unstructured":"Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors. https:\/\/www.bioinformation.net\/012\/97320630012149.htm. Accessed 29 Apr 2024"},{"key":"11063_CR16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/biomedicines9070793","volume":"9","author":"SS Sundararaman","year":"2021","unstructured":"Sundararaman SS, D\u00f6ring Y, van der Vorst EPC (2021) PCSK9: a multi-faceted protein that is involved in cardiovascular biology. Biomedicines 9:793. https:\/\/doi.org\/10.3390\/biomedicines9070793","journal-title":"Biomedicines"},{"key":"11063_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/prot.10389","volume":"52","author":"R Chen","year":"2003","unstructured":"Chen R, Li L, Weng Z (2003) ZDOCK: an initial-stage protein-docking algorithm. Proteins Struct Funct Bioinforma 52:80\u201387. https:\/\/doi.org\/10.1002\/prot.10389","journal-title":"Proteins Struct Funct Bioinforma"},{"key":"11063_CR18","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/ci6004299","volume":"47","author":"SN Rao","year":"2007","unstructured":"Rao SN, Head MS, Kulkarni A, LaLonde JM (2007) Validation studies of the site-directed docking program libdock. J Chem Inf Model 47:2159\u20132171. https:\/\/doi.org\/10.1021\/ci6004299","journal-title":"J Chem Inf Model"},{"key":"11063_CR19","unstructured":"Virtual screening, Docking, ADMET and System Pharmacology studies on Garcinia caged Xanthone derivatives for Anticancer activity | Scientific Reports. https:\/\/www.nature.com\/articles\/s41598-018-23768-7. Accessed 29 Apr 2024"},{"key":"11063_CR20","unstructured":"Molecular interaction analysis of cigarette smoke carcinogens NNK and NNAL with enzymes involved in DNA repair pathways: An in silico approach. https:\/\/www.bioinformation.net\/008\/97320630008795.htm. Accessed 29 Apr 2024"},{"key":"11063_CR21","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1021\/acs.jctc.0c00145","volume":"16","author":"X Ding","year":"2020","unstructured":"Ding X, Wu Y, Wang Y et al (2020) Accelerated CDOCKER with GPUs, Parallel simulated annealing, and fast fourier transforms. J Chem Theory Comput 16:3910\u20133919. https:\/\/doi.org\/10.1021\/acs.jctc.0c00145","journal-title":"J Chem Theory Comput"},{"key":"11063_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.862932","author":"L Yan","year":"2022","unstructured":"Yan L, Zhang Z, Liu Y et al (2022) Anticancer activity of erianin: cancer-specific target prediction based on network pharmacology. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2022.862932","journal-title":"Front Mol Biosci"},{"key":"11063_CR23","doi-asserted-by":"publisher","unstructured":"The dominant role of side\u2010chain backbone interactions in structural realization of amino acid code. ChiRotor: A side\u2010chain prediction algorithm based on side\u2010chain backbone interactions - Spassov - 2007 - Protein Science - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1110\/ps.062447107. Accessed 16 Jul 2024","DOI":"10.1110\/ps.062447107"},{"key":"11063_CR24","doi-asserted-by":"publisher","first-page":"117662","DOI":"10.1016\/j.molliq.2021.117662","volume":"343","author":"H Monhemi","year":"2021","unstructured":"Monhemi H (2021) Protein simulation in supercritical CO2: the challenge of force field. J Mol Liq 343:117662. https:\/\/doi.org\/10.1016\/j.molliq.2021.117662","journal-title":"J Mol Liq"},{"key":"11063_CR25","unstructured":"Manual-5.0.7.Pdf. In: Docslib. https:\/\/docslib.org\/doc\/2097233\/manual-5-0-7-pdf. Accessed 29 Apr 2024"},{"key":"11063_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1107\/S0907444904011679","volume":"60","author":"AW Sch\u00fcttelkopf","year":"2004","unstructured":"Sch\u00fcttelkopf AW, van Aalten DMF (2004) PRODRG: a tool for high-throughput crystallography of protein\u2013ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355\u20131363. https:\/\/doi.org\/10.1107\/S0907444904011679","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"11063_CR27","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1021\/acs.jpcb.8b02144","volume":"122","author":"MC Childers","year":"2018","unstructured":"Childers MC, Daggett V (2018) Validating molecular dynamics simulations against experimental observables in light of underlying conformational ensembles. J Phys Chem B 122:6673\u20136689. https:\/\/doi.org\/10.1021\/acs.jpcb.8b02144","journal-title":"J Phys Chem B"},{"key":"11063_CR28","doi-asserted-by":"publisher","first-page":"e0153999","DOI":"10.1371\/journal.pone.0153999","volume":"11","author":"FA Samad","year":"2016","unstructured":"Samad FA, Suliman BA, Basha SH et al (2016) A Comprehensive in silico analysis on the structural and functional impact of snps in the congenital heart defects associated with NKX2-5 gene\u2014a molecular dynamic simulation approach. PLoS ONE 11:e0153999. https:\/\/doi.org\/10.1371\/journal.pone.0153999","journal-title":"PLoS ONE"},{"key":"11063_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/ar000033j","volume":"33","author":"PA Kollman","year":"2000","unstructured":"Kollman PA, Massova I, Reyes C et al (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889\u2013897. https:\/\/doi.org\/10.1021\/ar000033j","journal-title":"Acc Chem Res"},{"key":"11063_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13721-020-00244-9","volume":"9","author":"EH Koushki","year":"2020","unstructured":"Koushki EH, Abolghasemi S, Mollica A et al (2020) Structure-based virtual screening, molecular docking and dynamics studies of natural product and classical inhibitors against human dihydrofolate reductase. Netw Model Anal Health Inform Bioinforma 9:49. https:\/\/doi.org\/10.1007\/s13721-020-00244-9","journal-title":"Netw Model Anal Health Inform Bioinforma"},{"key":"11063_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","volume":"210","author":"T Noguchi","year":"2010","unstructured":"Noguchi T, Katsuda S, Kawashiri M-A et al (2010) The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210:166\u2013172. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.11.018","journal-title":"Atherosclerosis"},{"key":"11063_CR32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/17474124.2021.1963231","volume":"15","author":"C Rubino","year":"2021","unstructured":"Rubino C, Trapani S, Indolfi G (2021) Sofosbuvir\/velpatasvir for the treatment of hepatitis C in pediatric patients. Expert Rev Gastroenterol Hepatol 15:1097\u20131105. https:\/\/doi.org\/10.1080\/17474124.2021.1963231","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"11063_CR33","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa2214299","volume":"388","author":"W Zi","year":"2023","unstructured":"Zi W, Song J, Kong W et al (2023) Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. N Engl J Med 388:2025\u20132036. https:\/\/doi.org\/10.1056\/NEJMoa2214299","journal-title":"N Engl J Med"},{"key":"11063_CR34","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/106002809102500510","volume":"25","author":"AB Cetnarowski-Cropp","year":"1991","unstructured":"Cetnarowski-Cropp AB (1991) Quinapril: a new second-generation ACE inhibitor. DICP Ann Pharmacother 25:499\u2013504. https:\/\/doi.org\/10.1177\/106002809102500510","journal-title":"DICP Ann Pharmacother"},{"key":"11063_CR35","doi-asserted-by":"publisher","unstructured":"Gengo FM, Brady E (1991) The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol 14:IV44\u201350; discussion IV51\u201355. https:\/\/doi.org\/10.1002\/clc.4960141807","DOI":"10.1002\/clc.4960141807"},{"key":"11063_CR36","unstructured":"Identification of novel inhibitors of Neisseria gonorrhoeae MurI using homology modeling, structure-based pharmacophore, molecular docking, and molecular dynamics simulation-based approach - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/36106953\/. Accessed 16 Jul 2024"},{"key":"11063_CR37","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S et al (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283:2363\u20132372. https:\/\/doi.org\/10.1074\/jbc.M708098200","journal-title":"J Biol Chem"},{"key":"11063_CR38","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.3390\/cells11192972","volume":"11","author":"C Liu","year":"2022","unstructured":"Liu C, Chen J, Chen H et al (2022) PCSK9 inhibition: from current advances to evolving future. Cells 11:2972. https:\/\/doi.org\/10.3390\/cells11192972","journal-title":"Cells"},{"key":"11063_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","volume":"48","author":"MJ Graham","year":"2007","unstructured":"Graham MJ, Lemonidis KM, Whipple CP et al (2007) Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48:763\u2013767. https:\/\/doi.org\/10.1194\/jlr.C600025-JLR200","journal-title":"J Lipid Res"},{"key":"11063_CR40","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","volume":"33","author":"E Crossey","year":"2015","unstructured":"Crossey E, Amar MJA, Sampson M et al (2015) A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33:5747\u20135755. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.044","journal-title":"Vaccine"},{"key":"11063_CR41","doi-asserted-by":"publisher","first-page":"115344","DOI":"10.1016\/j.bmc.2020.115344","volume":"28","author":"BJ Evison","year":"2020","unstructured":"Evison BJ, Palmer JT, Lambert G et al (2020) A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. Bioorg Med Chem 28:115344. https:\/\/doi.org\/10.1016\/j.bmc.2020.115344","journal-title":"Bioorg Med Chem"},{"key":"11063_CR42","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/nu12051440","volume":"12","author":"MP Adorni","year":"2020","unstructured":"Adorni MP, Zimetti F, Lupo MG et al (2020) Naturally occurring PCSK9 inhibitors. Nutrients 12:1440. https:\/\/doi.org\/10.3390\/nu12051440","journal-title":"Nutrients"},{"key":"11063_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.amjcard.2013.03.026","volume":"112","author":"G Bakris","year":"2013","unstructured":"Bakris G, Briasoulis A, Dahlof B et al (2013) Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol 112:255\u2013259. https:\/\/doi.org\/10.1016\/j.amjcard.2013.03.026","journal-title":"Am J Cardiol"},{"key":"11063_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003495-199448020-00008","volume":"48","author":"GL Plosker","year":"1994","unstructured":"Plosker GL, Sorkin EM (1994) Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 48:227\u2013252. https:\/\/doi.org\/10.2165\/00003495-199448020-00008","journal-title":"Drugs"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11063-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:03:32Z","timestamp":1758600212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11063-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["11063"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11063-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5387034\/v1","asserted-by":"object"}]},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,8]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}